Yesenia Rojas1, Yan X Shi1, Wei Zhang2, Elizabeth A Beierle3, John J Doski4, Melanie Goldfarb5, Adam B Goldin6, Kenneth W Gow6, Monica Langer7, Sanjeev A Vasudevan1, Jed G Nuchtern8. 1. Michael E. DeBakey Department of Surgery, Baylor College of Medicine, and Department of Surgery, Texas Children's Hospital, Houston, TX. 2. Outcomes and Impact Service, Department of Surgery, Texas Children's Hospital, Houston, TX. 3. Department of Surgery, University of Alabama, Birmingham, AL. 4. Department of Surgery, Methodist Children's Hospital of South Texas, University of Texas Health Science Center - San Antonio, San Antonio, TX. 5. Department of Surgery, John Wayne Cancer Institute/Providence St. Johns Medical Center, Santa Monica, CA. 6. Department of Surgery, Seattle Children's Hospital, University of Washington, Seattle, WA. 7. Department of Surgery, Maine Children's Cancer Program, Tufts University, Portland, ME. 8. Michael E. DeBakey Department of Surgery, Baylor College of Medicine, and Department of Surgery, Texas Children's Hospital, Houston, TX. Electronic address: nuchtern@bcm.edu.
Abstract
BACKGROUND: The purpose is to delineate the clinical and pathological characteristics of rare primary malignant pulmonary tumors in children. METHODS: Utilizing the National Cancer Data Base (NCDB), we analyzed all children (≤ 18 years) with a primary malignant pulmonary tumor from 1998 to 2011 to identify factors associated with better survival. RESULTS: Of 211 children identified, the most common histology was carcinoid tumor (n=133, 63%) followed by mucoepidermoid carcinoma (MEC) (n=37, 18%), squamous cell carcinoma (SCC) (n=19, 9%), adenocarcinoma (n=16, 8%), bronchoalveolar carcinoma (BAC) (n=4, 2%), and small cell carcinoma (SCLC) (n=2, <1%). Factors that significantly affected survival include histology, race, tumor size, lymph node status, and extent of surgery. Patients with MEC and carcinoid tumors had a better overall survival compared to patients with other histologies (p<0.0001). The 5-year overall survival for MEC and carcinoid tumors was 100% and 95% (95% CI 87-98), respectively, versus 50% (95%CI 1-91) for BAC, 28% (95%CI 9-52) for SCC, and 26% (95%CI 5-55) for adenocarcinoma. CONCLUSION: The majority of pediatric patients with a primary malignant pulmonary tumor present with carcinoid tumor or MEC and have an excellent prognosis. Lung cancers which are common in adults, but rare in children, have a worse prognosis.
BACKGROUND: The purpose is to delineate the clinical and pathological characteristics of rare primary malignant pulmonary tumors in children. METHODS: Utilizing the National Cancer Data Base (NCDB), we analyzed all children (≤ 18 years) with a primary malignant pulmonary tumor from 1998 to 2011 to identify factors associated with better survival. RESULTS: Of 211 children identified, the most common histology was carcinoid tumor (n=133, 63%) followed by mucoepidermoid carcinoma (MEC) (n=37, 18%), squamous cell carcinoma (SCC) (n=19, 9%), adenocarcinoma (n=16, 8%), bronchoalveolar carcinoma (BAC) (n=4, 2%), and small cell carcinoma (SCLC) (n=2, <1%). Factors that significantly affected survival include histology, race, tumor size, lymph node status, and extent of surgery. Patients with MEC and carcinoid tumors had a better overall survival compared to patients with other histologies (p<0.0001). The 5-year overall survival for MEC and carcinoid tumors was 100% and 95% (95% CI 87-98), respectively, versus 50% (95%CI 1-91) for BAC, 28% (95%CI 9-52) for SCC, and 26% (95%CI 5-55) for adenocarcinoma. CONCLUSION: The majority of pediatric patients with a primary malignant pulmonary tumor present with carcinoid tumor or MEC and have an excellent prognosis. Lung cancers which are common in adults, but rare in children, have a worse prognosis.
Authors: Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle Journal: Ecancermedicalscience Date: 2022-02-17
Authors: Lucia De Martino; Maria Elena Errico; Serena Ruotolo; Daniele Cascone; Stefano Chiaravalli; Paola Collini; Andrea Ferrari; Paolo Muto; Giuseppe Cinalli; Lucia Quaglietta Journal: J Med Case Rep Date: 2018-09-02
Authors: Marcos A Crespo; Victor M Villegas; Maria E Echevarria; Carmen M Gurrea; Timothy G Murray; Carlos M Chevere Journal: Case Rep Oncol Date: 2021-10-19